1. Home
  2. QH vs INAB Comparison

QH vs INAB Comparison

Compare QH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QH

Quhuo Limited American Depository Shares

N/A

Current Price

$3.98

Market Cap

10.8M

ML Signal

N/A

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$1.07

Market Cap

11.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
QH
INAB
Founded
2012
2016
Country
China
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.8M
11.8M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
QH
INAB
Price
$3.98
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
4.3K
36.9K
Earning Date
04-02-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.86
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.07
$0.88
52 Week High
$12.81
$2.73

Technical Indicators

Market Signals
Indicator
QH
INAB
Relative Strength Index (RSI) 42.19 44.87
Support Level $3.94 $0.96
Resistance Level $4.41 $1.22
Average True Range (ATR) 0.11 0.07
MACD 0.02 -0.00
Stochastic Oscillator 16.00 39.42

Price Performance

Historical Comparison
QH
INAB

About QH Quhuo Limited American Depository Shares

Quhuo Ltd is a gig economy platform focusing on local life services in China. It provide tech-enabled, end-to-end operational solutions to consumer service businesses, including on-demand delivery solutions, mobility service solutions, housekeeping and accommodation solutions, and other services. Its three operating segments, include (i) on-demand delivery solutions, (ii) mobility service solutions, and (iii) housekeeping and accommodation solutions and other services. It generates maximum of its revenue from the on-demand delivery solutions segment.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: